Plain-English translation of NCT04954859 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hepatitis B research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a long-term follow-up study for people with hepatitis B who participated in earlier trials of a medication called . Researchers want to understand how well the treatment continues to work months and years after the initial therapy ends. You would be monitored over time to see if your hepatitis B stays controlled.
Hepatitis B can be difficult to cure, and doctors need to know whether improvements from new treatments last over time. This study will help researchers understand the long-term durability of this medication's effects, especially in patients who may be able to stop taking their regular antiviral medicines.
You likely qualify if…
You likely don't qualify if…
You would be seen regularly by the research team over 33 months (about 2.5 years), with the possibility of extended follow-up for up to 5 years total if you maintain a good response. Visits will likely include blood tests to measure your viral load and hepatitis B surface antigen levels. If you are taking antiviral medication, you may be asked to stop it at a specific point in the study, but only if you meet certain safety criteria—and the study team will monitor you closely if you do.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States
Argentina
Bulgaria